Skip to main content
PMC home page
Gut logoLink to Gut
. 1997 Dec;41(6):735–739. doi: 10.1136/gut.41.6.735

One week triple therapy for Helicobacter pylori: a multicentre comparative study

J Misiewicz 1, A Harris 1, K Bardhan 1, S Levi 1, C O'Morain 1, B Cooper 1, G Kerr 1, M Dixon 1, H Langworthy 1, D Piper 1, H Lansoprazole 1
PMCID: PMC1891589  PMID: 9462204

Abstract

Background—Eradication of Helicobacter pylori cures and prevents the relapse of duodenal ulceration and also results in histological resolution of chronic active gastritis. 
Aim—To compare four treatment regimens lasting seven days of a proton pump inhibitor and two antibiotics in the eradication of H pylori. 
Patients—Men or women with H pylori positive duodenal ulceration or gastritis, or both. 
Methods—A single blind, prospectively randomised, parallel group, comparative, multicentre study. After a positive CLO test, patients underwent histology, H pylori culture, and a 13C urea breath test to confirm H pylori status. Treatment with one of four regimens: LAC, LAM, LCM, or OAM, where L is 30 mg of lansoprazole twice daily, A is 1 g of amoxycillin twice daily, M is 400 mg of metronidazole twice daily, C is 250 mg of clarithromycin twice daily, and O is 20 mg of omeprazole twice daily, was assigned randomly. A follow up breath test was done at least 28 days after completing treatment. 
Results—H pylori eradication (intention to treat) was 104/121 (86.0%) with LAC, 87/131 (66.4%) with LAM, 103/118 (87.3%) with LCM, and 94/126 (74.6%) with OAM. There was a significant difference (p < 0.001) in the proportion of patients in whom eradication was successful between LAC and LCM when compared with LAM, but no significant difference (p = 0.15) between LAM and OAM. Metronidazole resistance before treatment was identified as a significant prognostic factor with regard to eradication of H pylori. The regimens which contained metronidazole were significantly less effective than those without metronidazole in the presence of pretreatment resistant H pylori. There was no difference among the treatment groups with regard to the incidence and severity of adverse events reported. 
Conclusions—All four treatment regimens were safe and effective in eradicating H pylori in the patient population studied. LAC was the most efficacious treatment in patients with pretreatment metronidazole resistant H pylori, and was significantly better than LAM and OAM in this group of patients. 



Keywords: eradication; Helicobacter pylori; lansoprazole; omeprazole; metronidazole resistance

Full Text

The Full Text of this article is available as a PDF (113.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Banatvala N., Davies G. R., Abdi Y., Clements L., Rampton D. S., Hardie J. M., Feldman R. A. High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease. Gut. 1994 Nov;35(11):1562–1566. doi: 10.1136/gut.35.11.1562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bell G. D., Powell K. U., Burridge S. M., Bowden A. F., Atoyebi W., Bolton G. H., Jones P. H., Brown C. Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 1995 Feb;9(1):41–46. doi: 10.1111/j.1365-2036.1995.tb00349.x. [DOI] [PubMed] [Google Scholar]
  3. Coghlan J. G., Gilligan D., Humphries H., McKenna D., Dooley C., Sweeney E., Keane C., O'Morain C. Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study. Lancet. 1987 Nov 14;2(8568):1109–1111. doi: 10.1016/s0140-6736(87)91545-5. [DOI] [PubMed] [Google Scholar]
  4. Graham D. Y., Lew G. M., Malaty H. M., Evans D. G., Evans D. J., Jr, Klein P. D., Alpert L. C., Genta R. M. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992 Feb;102(2):493–496. doi: 10.1016/0016-5085(92)90095-g. [DOI] [PubMed] [Google Scholar]
  5. Harris A. W., Misiewicz J. J. Eradication of Helicobacter pylori. Baillieres Clin Gastroenterol. 1995 Sep;9(3):583–613. doi: 10.1016/0950-3528(95)90050-0. [DOI] [PubMed] [Google Scholar]
  6. Labenz J., Stolte M., Peitz U., Tillenburg B., Becker T., Börsch G. One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. Aliment Pharmacol Ther. 1996 Apr;10(2):207–210. doi: 10.1046/j.1365-2036.1996.727119000.x. [DOI] [PubMed] [Google Scholar]
  7. Marshall B. J., McGechie D. B., Rogers P. A., Glancy R. J. Pyloric Campylobacter infection and gastroduodenal disease. Med J Aust. 1985 Apr 15;142(8):439–444. doi: 10.5694/j.1326-5377.1985.tb113444.x. [DOI] [PubMed] [Google Scholar]
  10. Rauws E. A., Langenberg W., Houthoff H. J., Zanen H. C., Tytgat G. N. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology. 1988 Jan;94(1):33–40. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES